CHANGE IN RATINGS, EPS
Activision Blizzard (ATVI) estimates, target increased at BMO.Shares of ATVI now seen reaching $17. Estimates also increased on strong performances by Call of Duty and World of Warcraft. Outperform rating.
Activision Blizzard estimates increased at Citigroup through 2012. Strong beat and raise 3Q. Maintain $16 price target and Buy rating.
Adobe Systems (ADBE) estimates, target lowered at Jefferies.Shares of ADBE now seen reaching $35. Estimates also lowered as risk of growth reset has diminished. Buy rating.
Amdocs (DOX) estimates lowered at Citigroup through 2013. Modestly lower near term organic revenue growth. Maintain $37 price target and Buy rating.
Amylin Pharmaceuticals (AMLN) upgraded at BMO from Market Perform to Outperform. $17 price target. Confidence in BYDUREON approval.
Ares Capital (ARCC) estimates increased at UBS through 2012. 3Q results show value of platform. Maintain $19 price target and buy rating.
Ashland (ASH) downgraded to hold at TheStreet Ratings.
Autodesk (ADSK) downgraded at BofA/Merrill.ADSK was downgraded from Buy to Neutral. $38 price target. Recent reseller survey was downbeat. Company is also leveraged to weaker growth in Europe.
Babcock & Wilcox (BWC) numbers boosted at Credit Suisse. Shares of BWC now seen reaching $25. Estimates also upped, as the company is seeing higher growth across the board. Neutral rating.
Big Lots (BIG) rated new Hold at Keybanc. Company is a market leader, but lacks near-term catalysts.
BJ's Restaurants (BJRI) ! numbers raised at Oppenheimer. Shares of BJRI now seen $62, according to Oppenheimer. Estimates also boosted, as the company should continue to deliver solid growth. Outperform rating.
Eli Lilly (LLY) target reduced at Credit Suisse to $37, according to Credit Suisse. Company ceded control of exenatide to Amylin. Neutral rating.
Franklin Resources (BEN) numbers increased at Sterne Agee.BEN estimates were raised through 2013. Company is seeing strong asset growth. Buy rating and new $134 price target.
Globe Specialty Metals (GSM) estimates, target lowered at Jefferies.Shares of GSM now seen reaching $22.50. Estimates also lowered on a more conservative outlook for silicon metal contract prices. Buy rating.
GNC (GNC) estimates, target raised at Morgan Stanley.Shares of GNC now seen reaching $31. Estimates also increased, given solid comp sales growth. Overweight rating.
H&R Block (HRB) upgraded at Oppenheimer from Perform to Outperform. $19 price target. Company has multiple potential catalysts.
Hewlett Packard (HPQ) estimates, target lowered at Jefferies.Shares of HPQ now seen reaching $35. Estimates also lowered as Thailand floods create shortfall in April quarter. Buy rating.
Hibbett Sports (HIBB) downgraded at Longbow from Buy to Neutral. Valuation call, as the stock has gained 21% year-to-date.
HollyFrontier (HFC) estimates, target cut at Credit Suisse.Shares of HFC now seen reaching $47. Company will likely invest more toward future growth.
Int'l Flavors & Fragrances (IFF) numbers lowered at Credit Suisse.IFF estimates were cut through 2012. Company has! limited near-term visibility. Outperform rating and new $66 price target.
Medicis (MRX) target increased at UBS to $39. 3Q missed consensus, but in guided range. Neutral rating.
Medicis downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company faces potential growth headwinds.
Netsuite (N) rated new Outperform at Wells Fargo. Company is leveraged to secular growth in cloud computing.
Noble Energy (NBL) target raised at UBS to $113. Expect 2012 production guidance and improved long term growth outlook. Buy rating.
Nvidia (NVDA) downgraded at JMP to Market Perform. Estimates also cut, as the Tegra initiative is facing increased competition. $18 price target.
Quality Systems (QSII) upgraded at Stifel from Hold to Buy. $46 price target. Company offers growth at an attractive price.
Rite Aid (RAD) upgraded at Credit Suisse from Neutral to Outperform. $1.50 price target. Company has multiple potential near-term catalysts.
Rockwell Automation (ROK) estimates, target increased at UBS.Shares of ROK now seen reaching $79. Estimates also increased on solid 2012 outlook despite uncertain macro. Neutral rating.
Rosetta Resources (ROSE) estimates, target increased at BMO. Shares of ROSE now seen reaching $60. Estimates also raised on lower operating expenses. Outperform rating.
Rovi (ROVI) downgraded at Brean Murray from Buy to Hold. Company lacks visibility and there is a vacuum of power at the top.
Rovi downgraded at Collins Stewart from Buy to Neutral. $40 price target. Company slashed its guidance.
Salix Pharmaceuticals (SLXP) estimates increased at UBS through 2012. Modest accre! tion fro m Oceana. Maintain $32 price target and Neutral rating.
Scotts Miracle-Gro (SMG) estimates cut at Oppenheimer through 2012. Weaker sales are cutting into margins. Perform rating.
Solarwinds (SWI) estimates, target increased at Morgan Stanley.SWI estimates were raised through 2013. New products should help drive growth. Underweight rating and new $22 price target.
Solarwinds upgraded at Needham from Hold to Buy, Needham said. $36 price target. Company had an upbeat analyst meeting and can continue to grow.
Sunstone Hotel Investors (SHO) estimates, target raised at Jefferies.Shares of SHO now seen reaching $8, according to Jefferies. Estimates also raised as management continues to demonstrate solid execution. Hold rating.
Toll Brothers (TOL) numbers upped at Guggenheim. Shares of TOL now seen reaching $24, according to Guggenheim. Estimates also boosted, as the company is seeing higher orders across the board. Buy rating.
URS Corporation (URS) numbers raised at UBS. Shares of URS now seen reaching $38, according to UBS. Estimates also increased as private sector is expected to lead to 2012 growth. Neutral rating.
Vertex (VRTX) downgraded at Baird to Neutral, Robert Baird said. $33 price target. HCV business remains uncertain.
Viacom (VIAB) estimates, target reduced at Wedbush.Shares of VIA.B now seen reaching $55. Estimates also cut, given slower expected macro growth. Outperform rating.
Walgreen (WAG) downgraded at Credit Suisse from Outperform to Neutral. $31 price target. ESRX deal will likely be pushed out until next year.
No comments:
Post a Comment